DZ3506A1 - Derives de pyrrole utilises comme agents pharmaceutiques - Google Patents

Derives de pyrrole utilises comme agents pharmaceutiques

Info

Publication number: DZ3506A1
Authority: DZ; Algeria
Prior art keywords: pharmaceutical agents; pyrrole derivatives; pyrrole; derivatives; pharmaceutical
Prior art date: 2001-05-24

Application number

DZ023506A

Other languages

English (en)

Inventor

Jason Sawyer

Douglas Beight

Paola Ciapetti

Todd Decollo

Alexander Godfrey

Theodore Goodson

David Herron

Hong-Yu Li

Junkai Liao

William Mcmillen

Shawn Miller

Nicolas Mort

Jonathan Yingling

Edward Smith

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2002-05-15

Publication date

2002-11-28

2002-05-15 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-11-28 Application granted granted Critical

2002-11-28 Publication of DZ3506A1 publication Critical patent/DZ3506A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)

DZ023506A 2001-05-24 2002-05-15 Derives de pyrrole utilises comme agents pharmaceutiques DZ3506A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29346401P	2001-05-24	2001-05-24
PCT/US2002/011884 WO2002094833A1 (fr)	2001-05-24	2002-05-13	Derives de pyrrole utilises comme agents pharmaceutiques

Publications (1)

Publication Number	Publication Date
DZ3506A1 true DZ3506A1 (fr)	2002-11-28

Family

ID=23129192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ023506A DZ3506A1 (fr)	2001-05-24	2002-05-15	Derives de pyrrole utilises comme agents pharmaceutiques

Country Status (37)

Country	Link
US (1)	US7087626B2 (fr)
EP (1)	EP1397364B1 (fr)
JP (2)	JP4519407B2 (fr)
KR (1)	KR100861630B1 (fr)
CN (2)	CN1951939A (fr)
AR (1)	AR036034A1 (fr)
AT (1)	ATE368041T1 (fr)
AU (1)	AU2002339268B2 (fr)
BR (1)	BR0209939A (fr)
CA (1)	CA2446820C (fr)
CO (1)	CO5540282A2 (fr)
CY (1)	CY1106871T1 (fr)
CZ (1)	CZ303808B6 (fr)
DE (1)	DE60221392T2 (fr)
DK (1)	DK1397364T3 (fr)
DZ (1)	DZ3506A1 (fr)
EA (1)	EA007782B1 (fr)
EC (1)	ECSP034859A (fr)
EG (1)	EG25614A (fr)
ES (1)	ES2289116T3 (fr)
HR (1)	HRP20030961B1 (fr)
HU (1)	HU228844B1 (fr)
IL (2)	IL158512A0 (fr)
MX (1)	MXPA03010630A (fr)
MY (1)	MY134586A (fr)
NO (1)	NO326701B1 (fr)
NZ (1)	NZ528525A (fr)
PE (1)	PE20030117A1 (fr)
PL (1)	PL221339B1 (fr)
PT (1)	PT1397364E (fr)
SI (1)	SI1397364T1 (fr)
SK (1)	SK287857B6 (fr)
SV (1)	SV2003001054A (fr)
TW (1)	TWI329644B (fr)
UA (1)	UA76461C2 (fr)
WO (1)	WO2002094833A1 (fr)
ZA (1)	ZA200308546B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2289116T3 (es) *	2001-05-24	2008-02-01	Eli Lilly And Company	Nuevos derivados de pirrol como agentes farmaceuticos.
ES2292839T3 (es) *	2001-12-11	2008-03-16	Smithkline Beecham Corporation	Derivados de pirazolo-piridina como agentes contra el herpes.
EP1543001B1 (fr) *	2002-09-17	2007-08-15	Eli Lilly And Company	Derives de pyrazolopyridine en tant qu'inhibiteurs de tgf-beta pour le traitement des maladies de cancer
CA2506799A1 (fr) *	2002-11-21	2004-06-10	Eli Lilly And Company	Modulateurs de la kinase a lignee evolutive mixte
WO2004048381A2 (fr) *	2002-11-22	2004-06-10	Eli Lilly And Company	Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
UA80571C2 (en) *	2002-11-22	2007-10-10	Lilly Co Eli	Quinolinyl-pyrrolopyrazoles
AU2003290734A1 (en) *	2002-11-27	2004-06-23	Eli Lilly And Company	Novel compounds as pharmaceutical agents
CL2004000234A1 (es) *	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en) *	2003-11-12	2009-03-31	Eli Lilly And Company	Mixed lineage kinase modulators
EP1723146A1 (fr) *	2004-03-01	2006-11-22	Eli Lilly And Company	Derives de pyrazole fondu en tant qu'inhibiteurs de transduction de signal tgf-beta pour traiter les fibroses et les neoplasmes
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
AU2006228683B2 (en)	2005-04-01	2012-02-02	Vfp Therapies	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents
SI1910370T1 (sl) *	2005-07-22	2015-06-30	Eli Lilly And Company	Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor
WO2007021966A1 (fr)	2005-08-12	2007-02-22	Synta Pharmaceuticals Corp.	Composes pyrazoles modulant l'activite de la proteine hsp90
WO2007076127A2 (fr) *	2005-12-22	2007-07-05	Biogen Idec Ma Inc	Modulateurs du facteur de croissance transformant
DE102005061840A1 (de)	2005-12-23	2007-06-28	Merck Patent Gmbh	Triazolderivate
US8034834B2 (en)	2006-05-25	2011-10-11	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders with HSP90 inhibitors
DK2918288T3 (da)	2006-10-03	2017-11-27	Genzyme Corp	Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
ES2398677T3 (es) *	2007-12-12	2013-03-20	E. I. Du Pont De Nemours And Company	Pirazoles bicíclicos fungicidas
EP2373664B1 (fr) *	2008-12-19	2013-06-12	Nerviano Medical Sciences S.r.l.	Pyrazoles bicycliques en tant qu'inhibiteurs de protéines kinases
EP2419105A4 (fr) *	2009-04-17	2012-09-12	Summa Health Systems Llc	Utilisation de la transformation d'inhibiteurs de récepteur de facteur b de croissance pour supprimer une cicatrisation oculaire
AR081810A1 (es) *	2010-04-07	2012-10-24	Bayer Cropscience Ag	Piridinilpirazoles biciclicos
EP2560640A1 (fr)	2010-04-19	2013-02-27	Synta Pharmaceuticals Corp.	Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
EP2402339A1 (fr) *	2010-06-29	2012-01-04	Basf Se	Composés de pyrazolopyridine
EP2402337A1 (fr) *	2010-06-29	2012-01-04	Basf Se	Composés de pyrazolopyridine
EP2401915A1 (fr)	2010-06-29	2012-01-04	Basf Se	Composés de pyrazolopyridine
EP2402340A1 (fr)	2010-06-29	2012-01-04	Basf Se	Composés de pyrazolopyridine
EP2402338A1 (fr)	2010-06-29	2012-01-04	Basf Se	Composés de pyrazolopyridine
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (fr)	2011-04-08	2012-10-11	Aestus Therapeutics, Inc.	Procédés de traitement de la schizophrénie avec des inhibiteurs à base de dérivés du pyrazole de tgf-bêta
WO2013014262A1 (fr)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes de diagnostic et de traitement du syndrome de myhre
BR112014009789A2 (pt)	2011-10-26	2017-04-25	Seattle Children's Res Inst	cisteamina no tratamento da doença fibrótica
CA2853799A1 (fr)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Therapie anticancereuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomerase i
AU2012332424A1 (en)	2011-11-02	2014-06-05	Synta Pharmaceuticals Corp.	Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (fr)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
ES2966030T3 (es)	2012-10-05	2024-04-18	Kadmon Corp Llc	Anticuerpos anti-VEGFR-2/KDR humanos
TWI443096B (zh)	2012-12-18	2014-07-01	Ind Tech Res Inst	３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
JP2016507537A (ja) *	2013-02-07	2016-03-10	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	置換アセチレン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用
CA3184040A1 (fr)	2013-03-14	2014-10-02	The Brigham And Women's Hospital, Inc.	Compositions et methodes d'expansion de cellule souche epitheliale comprenant un agoniste de wnt et un inhibiteur d'histone desacetylase
US8975417B2 (en) *	2013-05-27	2015-03-10	Novartis Ag	Pyrazolopyrrolidine derivatives and their use in the treatment of disease
KR102408261B1 (ko)	2014-02-03	2022-06-10	비타이 파마슈티컬즈, 엘엘씨	Ror-감마의 디하이드로피롤로피리딘 저해제
WO2016037016A1 (fr)	2014-09-03	2016-03-10	The Brigham And Women's Hospital, Inc.	Compositions, systèmes et procédés pour la production de cellules ciliées de l'oreille interne pour le traitement de la perte auditive
JO3336B1 (ar)	2014-10-07	2019-03-13	Lilly Co Eli	مركبات أمينو بيريديلوكسي بيرازول
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3277673B1 (fr)	2015-04-01	2022-05-04	Rigel Pharmaceuticals, Inc.	Inhibiteurs du tgf-beta
EP3313420B1 (fr)	2015-06-25	2024-03-13	The Children's Medical Center Corporation	Procédés et compositions se rapportant à l'expansion, l'enrichissement et la conservation de cellules souches hématopoïétiques
US10301261B2 (en)	2015-08-05	2019-05-28	Vitae Pharmaceuticals, Llc	Substituted indoles as modulators of ROR-gamma
EP3868750A1 (fr)	2015-11-20	2021-08-25	Vitae Pharmaceuticals, LLC	Modulateurs de ror-gamma
AU2017205194A1 (en)	2016-01-08	2018-07-19	Massachusetts Institute Of Technology	Production of differentiated enteroendocrine cells and insulin producing cells
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
DK3429603T3 (da)	2016-03-15	2022-03-14	Childrens Medical Center	Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
RU2737737C2 (ru) *	2016-06-13	2020-12-02	Джинфлит Терапьютикс (Шанхай) Инк.	АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
KR102365333B1 (ko)	2016-07-29	2022-02-23	상하이 잉리 파마슈티컬 컴퍼니 리미티드	질소 함유 방향족 헤테로 고리 화합물, 이의 제조 방법, 약물 조성물 및 응용
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
PL3618829T3 (pl) *	2017-05-05	2023-11-20	Arcus Biosciences, Inc.	Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
WO2019018975A1 (fr)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	Inhibiteurs de ror gamma
CN111225914B (zh)	2017-07-24	2022-10-11	生命医药有限责任公司	RORγ的抑制剂
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt)	2017-10-05	2022-10-06	Fulcrum Therapeutics Inc	Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
AU2018348930A1 (en)	2017-10-11	2020-03-26	F. Hoffmann-La Roche Ag	Bicyclic compounds for use as RIP 1 kinase inhibitors
JP2021035911A (ja) *	2017-11-15	2021-03-04	大日本住友製薬株式会社	縮環ピラゾール誘導体及びその医薬用途
CN111479809B (zh)	2017-12-13	2021-10-29	劲方医药科技(上海)有限公司	一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN110066276B (zh)	2018-01-24	2020-09-18	上海璎黎药业有限公司	芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN110066277B (zh)	2018-01-24	2021-07-23	上海璎黎药业有限公司	芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
WO2019183245A1 (fr)	2018-03-20	2019-09-26	Icahn School Of Medicine At Mount Sinai	Composés inhibiteurs de kinase, compositions et procédés d'utilisation
US20210254006A1 (en)	2018-06-06	2021-08-19	Ideaya Biosciences, Inc.	Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN112867724B (zh) *	2018-07-23	2024-06-04	熙源安健医药(北京)有限公司	二膦酸盐药物缀合物
WO2020037326A1 (fr)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions et méthodes pour produire des cellules ciliées par la régulation à la baisse de foxo
US11162071B2 (en)	2018-08-17	2021-11-02	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating JAG-1
KR102126576B1 (ko)	2018-09-19	2020-06-24	주식회사 대웅제약	4-메톡시 피롤 유도체의 제조 방법
WO2020088526A1 (fr) *	2018-10-31	2020-05-07	南京明德新药研发有限公司	COMPOSÉ DOUBLE PYRAZOLE TENANT LIEU D'INHIBITEUR DU RÉCEPTEUR TCF-βR1 DE LA KINASE
CN113347965B (zh) *	2018-11-22	2025-02-18	生物医学研究机构基金会	TGFβ抑制剂和前药
AU2019417418B2 (en)	2018-12-27	2025-02-27	Nexys Therapeutics, Inc.	(pyridin-2-yl)amine derivatives as ΤGFβR1 (Alk5) inhibitors for the treatment of cancer
AU2019419414A1 (en)	2018-12-31	2023-04-06	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
JP7331116B2 (ja) *	2019-01-24	2023-08-22	チアンスーアオサイカンファーマシューティカルカンパニー，リミティド	ＴＧＦ－βＲ１キナーゼ阻害剤としての５－（４－ピリジルオキシ）ピラゾール類化合物
WO2020160151A1 (fr) *	2019-01-31	2020-08-06	Kyorin Pharmaceutical Co., Ltd.	Inhibiteurs de 15-pgdh
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) *	2019-06-10	2022-05-10	中国科学院广州生物医药与健康研究院	一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
WO2021142086A1 (fr)	2020-01-08	2021-07-15	Synthis Therapeutics, Inc.	Conjugués inhibiteurs d'alk5 et leurs utilisations
CN114867723B (zh) *	2020-07-23	2023-05-30	江苏奥赛康药业有限公司	作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
CN116249692B (zh)	2020-09-28	2024-08-23	四川科伦博泰生物医药股份有限公司	吡唑类化合物及其制备方法和用途
CN114437082B (zh) *	2020-11-06	2025-04-04	江苏先声药业有限公司	喹啉类化合物
CN115703750B (zh) *	2021-08-17	2024-07-02	黑龙江华瑞生物科技有限公司	一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) *	2021-11-22	2022-11-01	郑州大学	一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) *	2023-03-21	2023-08-25	劲方医药科技(上海)有限公司	用于癌症的药物组合物及其制备方法
WO2024258967A1 (fr)	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anticorps anti-cd5 et leurs utilisations
GB202309553D0 (en)	2023-06-24	2023-08-09	Ucl Business Ltd	Compostions and uses thereof
CN118652155A (zh) *	2024-06-17	2024-09-17	南京工业大学	一种二芳基乙炔的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356897A (en) *	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
EP0649425B1 (fr) *	1992-06-17	1999-03-10	PHARMACIA & UPJOHN COMPANY	Oximes a substitution pyridino, pyrrolidino et azepino, utilisees comme agents anti-atherosclerotiques et anti-hypercholesterolemiques
GB9303993D0 (en) *	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
CA2144330A1 (fr) *	1993-07-27	1995-02-09	Fumio Suzuki	Agent therapeutique pour la maladie de parkinson
US5358947A (en) *	1993-09-13	1994-10-25	American Cyanamid Company	Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
AUPN419395A0 (en) *	1995-07-17	1995-08-10	Treescope Development Co. Pty. Ltd.	Plant protector
FR2746306B1 (fr) *	1996-03-22	1998-04-30	Oreal	Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
TR200000235T2 (tr)	1997-05-22	2000-05-22	G.D. Searle &Co.	p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
FR2772379B1 (fr) *	1997-12-16	2000-02-11	Oreal	Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles
GB9809869D0 (en)	1998-05-09	1998-07-08	Medical Res Council	Inhibition of protein kinases
WO2000044743A1 (fr) *	1999-01-28	2000-08-03	Nippon Shinyaku Co., Ltd.	Derives d'amides et compositions de medicaments
DE60001229T2 (de)	1999-04-09	2003-10-30	Smithkline Beecham Corp., Philadelphia	Triarylimidazole
ES2222919T3 (es) *	1999-08-27	2005-02-16	Abbott Laboratories	Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2425288A1 (fr) *	2000-10-11	2002-05-02	Sander G. Mills	Modulateurs a base de pyrrolidine d'activite de recepteur de chimiokines ccr5
DE60203263T2 (de)	2001-02-02	2006-02-09	Smithkline Beecham Corp.	Pyrazolderivate gegen tgf überexprimierung
ES2289116T3 (es) *	2001-05-24	2008-02-01	Eli Lilly And Company	Nuevos derivados de pirrol como agentes farmaceuticos.
PL1633912T3 (pl) *	2003-05-28	2014-11-28	Oerlikon Textile Gmbh & Co Kg	Sposób oraz urządzenie do układania włókien wykorzystujące technikę igłowania powietrzem
JP4882198B2 (ja)	2003-09-25	2012-02-22	日産自動車株式会社	燃料電池システム

2002
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active Expired - Fee Related
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-13 CA CA2446820A patent/CA2446820C/fr not_active Expired - Fee Related
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 EP EP02744115A patent/EP1397364B1/fr not_active Expired - Lifetime
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/fr not_active Ceased
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending

Also Published As

Publication number	Publication date
EG25614A (en)	2012-03-22
KR20030097895A (ko)	2003-12-31
ES2289116T3 (es)	2008-02-01
EP1397364A1 (fr)	2004-03-17
HUP0400451A2 (hu)	2004-12-28
NO20035193L (no)	2003-11-21
CZ20033128A3 (cs)	2004-06-16
ECSP034859A (es)	2004-01-28
PT1397364E (pt)	2007-10-22
IL158512A (en)	2009-07-20
US7087626B2 (en)	2006-08-08
HRP20030961A2 (en)	2005-08-31
EP1397364B1 (fr)	2007-07-25
IL158512A0 (en)	2004-05-12
ATE368041T1 (de)	2007-08-15
CN1951939A (zh)	2007-04-25
PL221339B1 (pl)	2016-03-31
BR0209939A (pt)	2004-03-30
PE20030117A1 (es)	2003-02-12
JP2009197016A (ja)	2009-09-03
EA007782B1 (ru)	2007-02-27
CY1106871T1 (el)	2012-09-26
CA2446820A1 (fr)	2002-11-28
AR036034A1 (es)	2004-08-04
DE60221392T2 (de)	2008-04-17
ZA200308546B (en)	2005-04-26
US20040106604A1 (en)	2004-06-03
SV2003001054A (es)	2003-03-18
NO326701B1 (no)	2009-02-02
DE60221392D1 (de)	2007-09-06
EA200301289A1 (ru)	2004-06-24
WO2002094833A1 (fr)	2002-11-28
CA2446820C (fr)	2010-07-13
KR100861630B1 (ko)	2008-10-07
JP2004535404A (ja)	2004-11-25
HUP0400451A3 (en)	2008-08-28
HU228844B1 (en)	2013-06-28
DK1397364T3 (da)	2007-11-26
MXPA03010630A (es)	2004-03-09
SK14162003A3 (en)	2004-11-03
TWI329644B (en)	2010-09-01
CZ303808B6 (cs)	2013-05-09
CO5540282A2 (es)	2005-07-29
SK287857B6 (sk)	2012-01-04
PL367199A1 (en)	2005-02-21
AU2002339268B2 (en)	2007-05-31
NO20035193D0 (no)	2003-11-21
JP4519407B2 (ja)	2010-08-04
UA76461C2 (en)	2006-08-15
CN1269820C (zh)	2006-08-16
HRP20030961B1 (en)	2012-01-31
MY134586A (en)	2007-12-31
NZ528525A (en)	2005-10-28
CN1511157A (zh)	2004-07-07
HK1064375A1 (en)	2005-01-28
SI1397364T1 (sl)	2007-12-31

Publication	Publication Date	Title
DZ3506A1 (fr)	2002-11-28	Derives de pyrrole utilises comme agents pharmaceutiques
FR08C0007I2 (fr)	2009-01-15	Derives du triazolyltropane utilises comme modulateurs de ccr5
DZ3197A1 (fr)	2001-04-26	Acides aminés bicycliques utilises comme agents pharmaceutiques.
EP1773768A4 (fr)	2008-08-06	Derives de pyrrole en tant qu'agents pharmaceutiques
MA26344A1 (fr)	2004-10-01	Derives 1,8-naphtyridine utilises comme antidiabetiques
PT1147083E (pt)	2004-09-30	Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao
PT1406628E (pt)	2006-06-30	Derivados de tera-hidroquinolina
DZ3439A1 (fr)	2001-12-13	Derives de 2-aminocarbonyl-9h-purine
FR07C0057I2 (fr)	2008-05-16	Derives de pleuromutiline utilises comme agents antimicrobiens
IL229160B (en)	2018-08-30	Rapamycin derivatives for treatment of solid tumors
FR15C0068I2 (fr)	2016-04-22	Derives de diamine
NO20013671L (no)	2001-09-26	Substituerte bisycliske derivater nyttige som anticancer midler
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
PT1287001E (pt)	2004-12-31	Derivados de tiofeno uteis como agentes anticancerigenos
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
AR027967A1 (es)	2003-04-16	Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos
NO20033785D0 (no)	2003-08-26	Farmasöytisk formulering
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
EP1385868A4 (fr)	2004-12-08	Derives de steroides
EP1545509A4 (fr)	2008-10-22	Inhibiteurs de la caspase utilises comme agents anticancereux
FR2810318B1 (fr)	2005-09-23	Derives de diamano-phenothiazine
PT1154988E (pt)	2004-12-31	Derivados de mevinolina
AR028602A1 (es)	2003-05-14	Derivados de pirrol
AR028282A1 (es)	2003-04-30	Derivados de aminofenil pirimidona